Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical-stage biopharmaceutical company, is currently making waves in the biotech sector with its promising pipeline of cancer therapies. With a market capitalization of $1.1 billion, Oric is focused on developing treatments that combat resistance mechanisms in cancer, a challenge that continues to puzzle the oncology field.

The company’s stock is currently priced at $11.33, showing a modest increase of 0.05% recently. Over the past year, Oric’s stock has oscillated between $4.26 and $14.41, reflecting the volatility typical of biotech stocks. However, the real intrigue lies in the potential upside, as analysts have set a target price range between $15.00 and $25.00, with an…